REGULATION OF A-L-FUCOSIDASE IN HEALTH AND DISEASE

A-L-岩藻糖苷酶对健康和疾病的调节

基本信息

  • 批准号:
    3230613
  • 负责人:
  • 金额:
    $ 6.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1985
  • 资助国家:
    美国
  • 起止时间:
    1985-04-01 至 1988-03-31
  • 项目状态:
    已结题

项目摘要

Levels of Alpha-L-fucosidase in serum of ostensibly healthy individuals are genetically determined. The mechanism controlling levels of the enzyme in serum is unknown. As an experimental tool to investigate this problem, lymphoid cell cultures derived from individuals who have inherited either high or low activity of Alpha-L-fucosidase in serum will be established. With these cell lines, the following questions will be asked: 1) Are there differences in the relative rates of synthesis of the polypeptide and carbohydrate chains of Alpha-L-fucosidase? 2) Are there differences in the processing the polypeptide and/or carbohydrate moieties of Alpha-L-fucosidase? 3) Are there differences in the sorting of Alpha-L-fucosidase into intracellular and extraccellular compartments? 4) Are there differences in Alpha-L-fucosidase m-RNA activity? Answers to these questions will provide novel information concerning the biosynthesis and processing of Alpha-L-fucosidase and will contribute to an understanding of the mechanism determining levels of Alpha-L-fucosidase in serum. This knowledge, besides being scientifically important, may also have clinical significance. The inheritance of decreased activity of Alpha-L-fucosidae in serum of females has been associated with increased risk for developing ovarian cancer. Thus, an understanding of the mechanism controlling levels of Alpha-L-fucosidase in serum may provide information concerning the etiology of ovarian cancer and the genetic factors involved in disease susceptibility. Moreover, alterations of Alpha-L-fucosidase have been associated with other severe diseases. These include fucosidosis, I-cell disease, cystic fibrosis, gastric cancer, diabetes mellitus, hepatic cirrhosis, acute viral hepatitis, Graves disease, various muscular diseases and acute and chronic lymphoblastic leukemia. Thus, the proposed investigations may be relevant for an improved understanding of the molecular pathology of these diseases.
表面健康个体血清中的α-L-岩藻糖苷酶水平 基因决定的。 控制酶水平的机制 血清未知。 作为研究这个问题的实验工具, 淋巴细胞培养物来源于遗传了以下任一基因的个体 将确定血清中α-L-岩藻糖苷酶高或低活性。 对于这些细胞系,将提出以下问题:1)是否存在 多肽合成的相对速率的差异, α-L-岩藻糖苷酶的糖链 2)是否存在差异, 处理以下的多肽和/或碳水化合物部分: α-L-岩藻糖苷酶 3)在排序上是否存在差异 α-L-岩藻糖苷酶进入细胞内和细胞外区室? 四、 α-L-岩藻糖苷酶mRNA活性是否存在差异? 的答案 这些问题将提供有关生物合成的新信息 和加工α-L-岩藻糖苷酶,并将有助于 了解α-L-岩藻糖苷酶水平的决定机制, 血清的 这些知识,除了在科学上很重要之外, 具有临床意义。 活动减少的遗传 女性血清中的α-L-岩藻糖苷酶与增加的 患卵巢癌的风险。 所以,理解 控制血清中α-L-岩藻糖苷酶水平的机制可以提供 关于卵巢癌的病因学和遗传学的信息 与疾病易感性有关的因素。 此外, α-L-岩藻糖苷酶与其他严重疾病有关。 这些 包括岩藻糖苷病、I-细胞病、囊性纤维化、胃癌 糖尿病,肝硬化,急性病毒性肝炎,Graves 疾病,各种肌肉疾病和急性和慢性淋巴细胞性疾病 白血病 因此,拟议的调查可能与 提高对这些疾病的分子病理学的理解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RICHARD A DI CIOCCIO其他文献

RICHARD A DI CIOCCIO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RICHARD A DI CIOCCIO', 18)}}的其他基金

REGULATION OF ALPHA-L-FUCOSIDASE IN HEALTH AND DISEASE
α-L-岩藻糖苷酶在健康和疾病中的调节
  • 批准号:
    2138764
  • 财政年份:
    1985
  • 资助金额:
    $ 6.63万
  • 项目类别:
REGULATION OF ALPHA-L-FUCOSIDASE IN HEALTH AND DISEASE
α-L-岩藻糖苷酶在健康和疾病中的调节
  • 批准号:
    3230615
  • 财政年份:
    1985
  • 资助金额:
    $ 6.63万
  • 项目类别:
REGULATION OF ALPHA-L-FUCOSIDASE IN HEALTH AND DISEASE
α-L-岩藻糖苷酶在健康和疾病中的调节
  • 批准号:
    3230611
  • 财政年份:
    1985
  • 资助金额:
    $ 6.63万
  • 项目类别:
REGULATION OF A-L-FUCOSIDASE IN HEALTH AND DISEASE
A-L-岩藻糖苷酶对健康和疾病的调节
  • 批准号:
    3152443
  • 财政年份:
    1985
  • 资助金额:
    $ 6.63万
  • 项目类别:
REGULATION OF A-L-FUCOSIDASE IN HEALTH AND DISEASE
A-L-岩藻糖苷酶对健康和疾病的调节
  • 批准号:
    3230614
  • 财政年份:
    1985
  • 资助金额:
    $ 6.63万
  • 项目类别:

相似海外基金

Development of B cell functional studies on primary antibody deficiencies
一抗缺陷 B 细胞功能研究的进展
  • 批准号:
    502607
  • 财政年份:
    2024
  • 资助金额:
    $ 6.63万
  • 项目类别:
Thymus antibody-secreting cells: major players in autoimmunity.
胸腺抗体分泌细胞:自身免疫的主要参与者。
  • 批准号:
    502578
  • 财政年份:
    2024
  • 资助金额:
    $ 6.63万
  • 项目类别:
ICF: AbVax Combination vaccination and broadly neutralising antibody therapy in HIV to induce a protective Tcell vaccinal effect, a mechanistic study
ICF:AbVax 联合疫苗接种和广泛中和 HIV 抗体疗法诱导保护性 T 细胞疫苗效应,一项机制研究
  • 批准号:
    MR/Y008847/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.63万
  • 项目类别:
    Research Grant
Enabling The Targeted Delivery Of DNA G-quadruplex Ligands using a Novel Antibody DAR-1 Platform
使用新型抗体 DAR-1 平台实现 DNA G 四链体配体的靶向递送
  • 批准号:
    BB/Y002180/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.63万
  • 项目类别:
    Research Grant
Antibody-Palladium Conjugates for Bioorthogonal Anti-Cancer Prodrug Activation
用于生物正交抗癌前药激活的抗体-钯缀合物
  • 批准号:
    EP/Y024540/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.63万
  • 项目类别:
    Fellowship
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
  • 批准号:
    24K19237
  • 财政年份:
    2024
  • 资助金额:
    $ 6.63万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
A Semi-Automated Antibody-Discovery Platform to Target Challenging Biomolecules
针对具有挑战性的生物分子的半自动化抗体发现平台
  • 批准号:
    MR/Y003616/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.63万
  • 项目类别:
    Fellowship
Monitoring antibody protection against SARS-CoV-2 variants
监测抗体对 SARS-CoV-2 变体的保护作用
  • 批准号:
    MR/Y033698/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.63万
  • 项目类别:
    Research Grant
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    $ 6.63万
  • 项目类别:
    Operating Grants
Pharmacokinetic analysis of antibody drug conjugate in tumor cells utilizing synchrotron soft X-ray imaging
利用同步加速器软 X 射线成像对肿瘤细胞中抗体药物偶联物进行药代动力学分析
  • 批准号:
    23H03716
  • 财政年份:
    2023
  • 资助金额:
    $ 6.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了